Team:ATOMS-Turkiye
From 2014.igem.org
Line 78: | Line 78: | ||
<li><img src="https://static.igem.org/mediawiki/2014/thumb/a/aa/ATOMS-main-9.jpg/800px-ATOMS-main-9.jpg" title= "With our novel sensing and protective systems, evaluation of clinical presence will no longer be required to treat hypoxic conditions."></li> | <li><img src="https://static.igem.org/mediawiki/2014/thumb/a/aa/ATOMS-main-9.jpg/800px-ATOMS-main-9.jpg" title= "With our novel sensing and protective systems, evaluation of clinical presence will no longer be required to treat hypoxic conditions."></li> | ||
- | <li><img src="https://static.igem.org/mediawiki/2014/thumb/7/78/ATOMS-main-10.jpg/800px-ATOMS-main-10.jpg" title= " | + | <li><img src="https://static.igem.org/mediawiki/2014/thumb/7/78/ATOMS-main-10.jpg/800px-ATOMS-main-10.jpg" title= "Hence, our unique design of mechanism will now be a remedy to the leading cause of deaths worldwide. "></li> |
</ul> | </ul> | ||
Latest revision as of 03:55, 18 October 2014
Project Abstract
The condition which results in tissue death due to the poor conveyance of oxygen and other products vital for tissue cells and organs is described as tissue hypoxia or ischemia. Currently, ischemia and other related conditions such as heart attacks and strokes take the lead for being the number one cause of death worldwide. Moreover, the current treatment of ischemic attacks can intensify the damage in the tissue caused by hypoxia which is known as oxidative stress. This is due to the high oxygen concentration of the restored blood supply. Without a doubt, we need to view the bigger picture of the condition in order to solve this problem. In our project, we desire to build two different devices which work synergistically and fix these these two distinct situations, hypoxia and oxidative stress. Hence, we have decided to use "hypoxia inducible systems" and "reactive oxygen species (ROS) sensitive gene fragments". These two receptors will regulate the release of clot dissolving factors and antioxidant peptides synthesized by our engineered vessel cells. Through attaining encouraging in-vitro results, we aim to pave the way of this promising system into a lifesaving remedy.
-
ModelingThis year we carried out mathematical modeling to comprehend how our promoter system would react against hypoxia in order to treat heart related problems. In addition to this, we have also modeled our safety experiment to show its successful outcome mathematically. For more information, click here... This year, we have carried out ....
-
BioBricksOur team proposes seven new eukaryotic cell parts to the Registry consisting of three promoters and four different enzymes with various capabilities. To get detailed information, proceed here. Our team proposes seven new eukaryotic cell parts ...